Biotechnology

XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics Discovery

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation to advance the discovery and evolution of groundbreaking th...

2024-01-30 21:00 1182

Singleron launches the AccuraSCOPE® Single Cell Transcriptome

COLOGNE, Germany, Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine,announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length...

2024-01-30 18:05 1100

DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD

* The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD. • DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor with excellent in vivo efficacy and safety profile in preclinical studies.  * This project fur...

2024-01-30 16:32 1370

Vesicure Therapeutics made notable advancements using exosomes to target KRAS mutation

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene. This technology has emerged as a great strategy for treating a range of diseases, including cancer, viral infections, and genetic...

2024-01-29 21:30 1240

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for patients with...

2024-01-29 21:08 1390

Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer

CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr.Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO). Dr. Wu brings with him more than three decades of experience in the field of...

2024-01-29 21:00 920

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the charge in small activating RNA (saRNA) therapeutics, announces a formal collaboration with University Medical Center Utrecht, affiliated withUtrecht University. This strategic ...

2024-01-29 21:00 979

Angel Yeast's 2024 New Year's Resolutions: Advancing Development through Technological Innovation

SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Angel Yeast (SH600298), the world's leading yeast manufacturer, is excited to share its resolutions for 2024. Building upon the achievements of 2023 and upholding high standards across various indicators,Angel Yeast is dedicated ...

2024-01-29 20:44 1540

deCODE genetics: A sequence variant that increases risk of pregnancy loss

REYKJAVIK, Iceland, Jan. 29, 2024 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and theUSA published a study today in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates ...

2024-01-29 18:00 1409

Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU

SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the release of ...

2024-01-29 16:17 1260

Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF THE CONTACT PERSONS SET OUT BELOW, ONJANUARY 26, 2024, AT 11:20 FINNISH TIME / 10:20 SWEDISH TIME. HELSINKI, ...

2024-01-26 20:08 1735

AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site

* US$223 million expansion will add biologics capacity to AbbVie manufacturing network * Singapore manufacturing site to grow to more than 500 employees following expansion * Construction will commence immediately with facilities becoming operational in 2026 SINGAPORE, Jan. 26, 2024 /PRNews...

2024-01-26 08:30 5586

Ceva Santé Animale acquires Scout Bio, paving the way for groundbreaking innovations in pet therapeutics

LIBOURNE, France, Jan. 26, 2024 /PRNewswire/ -- Ceva Santé Animale (Ceva), the #5 animal health company present in 110 countries worldwide, announcesthe strategic acquisition of Scout Bio, a pioneer in biotechnology focused on cutting-edge therapies for pets. The move represents a significant lea...

2024-01-26 06:00 2386

First International Shipment of HANSIZHUANG Launched

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying anti-PD-1 mAb Zerpidio® (serplulimab, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of benefiting patients worldwide with high-quality biopharmaceuticals...

2024-01-25 21:41 1867

First International Shipment of HANSIZHUANG

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying HANSIZHUANG Zerpidio® (anti-PD-1 monoclonal antibody, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of "benefiting patients worldwide with high-quality ...

2024-01-25 20:45 3839

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...

2024-01-25 18:38 1640

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...

2024-01-25 18:00 1520

Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the interi...

2024-01-25 16:56 1328

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

-  WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse bioprocessing solutions for global clients -  WuXiaADCC PLU...

2024-01-25 08:30 1258

FDA purchases digiM I2S software for the assessment of product quality attributes

Reviewers and regulatory researchers to use AI image analytics for process-quality correlation WOBURN, Mass., Jan. 24, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration has placed a purchase order (75F40123P00369) committing to an annual subscription of digiM I2S, a fully integrated ima...

2024-01-24 23:37 1337
1 ... 891011121314 ... 275

Week's Top Stories